Samsung Biologics
207940.KS207940.KS · Stock Price
Historical price data
Overview
Samsung Biologics is a mission-driven CDMO focused on accelerating the development and manufacturing of biologics for its global clientele. The company has achieved rapid growth to become one of the world's largest biologics manufacturers by capacity through aggressive facility expansion, including the world's largest single plant, and strategic geographic moves like acquiring a U.S. facility from GSK. Its strategy is built on integrating cutting-edge technology platforms, ensuring regulatory excellence, and forging deep strategic partnerships to provide unparalleled speed, scale, and flexibility in biologics production.
Technology Platform
An integrated suite of proprietary platforms spanning the biologics value chain, including the S-CHOice® cell line development system, Patient-Derived Tumor Organoid (PDO) screening, and dedicated platforms for ADCs and continuous perfusion manufacturing.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Competes directly with global CDMO leaders like Lonza, WuXi Biologics, and Catalent. Its primary advantages are unmatched scale and speed of capacity deployment, strong financial backing from the Samsung Group, a proven track record of operational excellence, and an integrated end-to-end service offering.
